Stock analysts at Zacks Research upped their Q1 2025 EPS estimates for Editas Medicine in a report released on Wednesday, ...

Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Zacks Research issued their FY2027 earnings per share (EPS) estimates for Editas Medicine in a report released on Wednesday, March 26th.

Trump also nominated Republican attorney Thomas March Bell to lead the Department of Health and Human Service’s Office of Inspector General. Calley Means, a chronic disease entrepreneur and ...

At meeting on human embryo editing, CRISPR pioneer says science is a long way from knowing if germline DNA can be safely ...

Editas Medicine , Inc. (NASDAQ: NASDAQ:EDIT) stock has tumbled to a 52-week low, reaching a price level of just $2.7. This ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

EMERYVILLE, CA, USA I March 26, 2025 I Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

After hours: 26 March at 7:54:10 pm GMT-4 Loading Chart for EDIT ...

At close: March 27 at 4:00:01 PM EDT ...

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...